What are your top takeaways from ASCO GI 2022?  

1. "NEONIPIGA” GERCOR: While small numbers of patients, they evaluated an immunotherapy combination in MSI-H locally advanced gastric or GE junction cancer. They demonstrated high rates of responses and 59% path CR which is unprecedented in patients undergoing surgery. It raises the question o...

1. HIMALAYA: offering a new IO option in HCC 2. KRYSTAL-1: offering a new avenue for kras G12C targetability in a host of GI tumors (including PDAC!) 3. TOPAZ: With durvalumab added to gem/cis looking like a new promising chemo-IO combo in BTC that builds on the longstanding 1st-lin...

1. TOPAZ-1: In the topaz-1 trial, durvalumab was added to the standard of care treatment gemcitabine and cisplatin and compared this to chemotherapy alone. The addition of the pdl-1 inhibitor, the durvalumab group had improved OS with a hazard ratio (HR) of 0.80 (95% CI, 0.66-0.97; P = .021). This w...

1. TOPAZ: Cholangiocarcinoma showing benefit to the addition of durvalumab to gem/cis chemo for first line treatment. I'm likely to add durva to my first line regimen now (once insurance gets on board). 2. HIMALAYA: With benefit of durvalumab/tremetinib over first like sorafenib in HCC first line. ...

1. ctDNA study: Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. 2. TOPAZ-1: A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combinati...

1. TOPAZ-1: Durva +/- gem/cis front-line biliary tract cancerQuestion of applicability to Western patient population (i.e., non-Asian), question of whether benefit is from maintenance vs induction durva. 2. HIMALAYA: Tremi +/- durva vs sorafenib front-line HCCCrowded first-line options, atezo/bev s...